Dianne Whitfield Sells 7,397 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Tarsus Pharmaceuticals Stock Performance

TARS stock traded down $0.29 during mid-day trading on Thursday, hitting $77.48. 446,436 shares of the company were exchanged, compared to its average volume of 632,110. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The stock has a market capitalization of $3.29 billion, a PE ratio of -38.36 and a beta of 0.74. The business has a 50 day simple moving average of $74.77 and a 200-day simple moving average of $57.68. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The business had revenue of $118.70 million during the quarter, compared to analysts’ expectations of $114.22 million. On average, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after acquiring an additional 339 shares during the period. Creative Planning boosted its stake in Tarsus Pharmaceuticals by 3.3% during the third quarter. Creative Planning now owns 12,367 shares of the company’s stock worth $735,000 after acquiring an additional 393 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in Tarsus Pharmaceuticals by 6.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,626 shares of the company’s stock worth $349,000 after purchasing an additional 505 shares during the period. Finally, Quarry LP grew its holdings in Tarsus Pharmaceuticals by 20.0% in the first quarter. Quarry LP now owns 3,599 shares of the company’s stock worth $185,000 after purchasing an additional 599 shares during the period. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. HC Wainwright increased their price target on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, October 20th. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Mizuho started coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $51.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $79.86.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.